Novel Treatment Options for Multiple Myeloma – Live

Description

Program Description

---

Click to Go to the Event Registration

Multiple myeloma (MM) is characterized by the neoplastic proliferation of plasma cell clones that produce monoclonal immunoglobulin. These plasma cell clones proliferate in the bone marrow causing skeletal damage, a hallmark of MM. Other disease-related complications include hypercalcemia, renal insufficiency, anemia, and infections. MM accounts for approximately 1.8% of all cancers and slightly more than 17% of hematologic malignancies in the United States. MM is relatively rare, but it is more common in men than women and African Americans compared with whites. B-cell maturation antigen (BCMA) has emerged as a promising target for MM therapies. Almost all patients with MM eventually relapse. The remission duration in relapsed/refractory MM (RRMM) decreases with each regimen. The practice of choosing the subsequent best therapy for patients with RRMM is becoming increasingly complex. There is no clear consensus regarding the best treatment sequence for RRMM. The following novel therapies have been approved for MM: proteasome inhibitors (carfilzomib, ixazomib), immunomodulatory agents (pomalidomide), monoclonal antibodies (daratumumab, elotuzumab, and isatuximab), and anti-BCMA targeted therapies are being studied to enhance disease control, prolong progression-free survival, and improving overall survival. This activity offers a new paradigm in selecting treatment regimens, focusing on patient-specific morbidity, treatment toxicity, and disease-specific characteristics.

Agenda

---

• Clinical Vignette 1 (Pretest –Audience polling)
• Overview treatment guidelines, cytogenetic and genomic testing, selection, and sequencing therapies for patients with multiple myeloma (MM)
• Clinical Vignette 1 (Post-test –Audience polling)
• Clinical Vignette 2 (Pretest –Audience polling)
• Combination therapy options for patients with relapsed/refractory multiple myeloma (RRMM)
• Clinical Vignette 2 (Post-test –Audience polling)
• Clinical Vignette 3 (Pretest – Audience polling)
• The BCMA as a therapeutic target and advantages of CAR-modified T-cell therapy for patients with RRMM
• Clinical Vignette 3 (Post-test –Audience polling)
• Clinical Vignette 4 (Pretest –Audience polling)
• The therapeutic potential of bispecific T-cell engager and monoclonal antibody-drug conjugate (ADC) in the treatment of patients with RRMM
• Clinical Vignette 4 (Posttest –Audience polling)
• Questions from Participants and panel Discussion

Intended Audience

---

Hematologists/oncologists, nurse practitioners, physician assistants, and nurses.

Commercial Supporter

---

This activity is supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.